With wildfires burning and Covid-19 spreading, can California afford stem cell research? Voters are set to decide
By Usha Lee McFarling,
STAT
| 10. 26. 2020
LOS ANGELES — This Election Day, California voters are being asked to replenish funding for the state’s ambitious stem cell research program, with a well-financed campaign that’s making heady promises about curing diabetes, paralysis, cancer, and Parkinson’s and Alzheimer’s diseases.
Backers of Proposition 14 also cast it as a job-creation measure, arguing the money it raises will boost the state economy by cementing the Golden State’s place as a leading incubator of successful biotech startups. But opponents say that amid the Covid-19 pandemic and wildfires, California has far more pressing needs.
In 2004, Californians approved a $3 billion ballot measure, Proposition 71, to create a new state agency to fund stem cell research at a time when President George W. Bush had banned federal funding for some of this work — if scientists used newly created embryonic stem cell lines. Now, even though the National Institutes of Health funds stem cell research to the tune of $2 billion a year, California residents are being asked to authorize the sale of $5.5 billion in general obligation bonds to pay for stem...
Related Articles
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...
By Peter Aldhous, Scientific American | 07.02.2024
In June a notice posted on the website of the journal Nature set a new scientific record. It withdrew what is now the most highly cited research paper ever to be retracted.
The study, published in 2002 by Catherine Verfaillie...